Casper H van Eijck

23PUBLICATIONS
99CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Jun 12, 2026
CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting.

|Feb 27, 2026
The Value of Stereotactic Radiotherapy After FOLFIRINOX in Patients with Pancreatic Cancer with Vascular Contact-A Nationwide, Retrospective Cohort Study.

Freek R van 't Land, Leonard W F Seelen, Maaike Verheij

|Jan 29, 2026
Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial.

Ruth A L Willems, Aniek E van Diepen, Esther N Dekker

|Nov 28, 2025
REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer.

Songul Kucukcelebi, Freek R van 't Land, Sjoerd H van der Burg

|Feb 01, 2025
Preoperative stereotactic radiotherapy to prevent pancreatic fistula in high-risk patients undergoing pancreatoduodenectomy (FIBROPANC): prospective multicentre phase II single-arm trial.

Leonoor V Wismans, Tessa E Hendriks, J Annelie Suurmeijer

|Nov 06, 2024
A new era with advanced immunotherapy.

Claudia Badia Lopez, Elisabeth Ruijgrok, Casper H J van Eijck

Pageof 4

Frequent Collaborators

8 joint publications

Dana A Mustafa

6 joint publications

Marc G H Besselink

6 joint publications

Bas Groot Koerkamp

5 joint publications

Casper W F van Eijck